Wenger Vieli as Swiss legal advisor for NLS Pharmaceutics

NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company, has entered into a definitive agreement with BVF PARTNERS to raise aggregate gross proceeds of up to USD 30.0 million in a two-tranche private placement. 

The net proceeds will enable the Swiss clinical-stage biopharmaceutical company to advance the ongoing clinical development of its products and further support business development and licensing activities. 

Wenger Vieli has acted as Swiss legal advisor to NLS Pharmaceutics on all Swiss legal aspects in connection with the PIPE transaction. The team was led by Pascal Honold (partner, m&a/vc/pe) and included Kevin Wilhelm Vangehr (associate, m&a/vc/pe), Alessa Waibel (associate, financial services), Andrea Christen (associate, m&a/vc/pe) and Mark P. Stocker (associate, notarial services).